Nadler J P, Berger J, Nord J A, Cofsky R, Saxena M
Department of Medicine, State University of New York Health Science Center, Brookdale Hospital, Brooklyn.
Chest. 1991 Apr;99(4):1025-6. doi: 10.1378/chest.99.4.1025.
This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.
本报告描述了两名耐多药结核病患者，他们在二线药物治疗中加用阿莫西林-克拉维酸后成功治愈。结核分枝杆菌具有一种β-内酰胺酶，这使其对β-内酰胺类抗生素产生耐药性。β-内酰胺酶抑制剂克拉维酸与阿莫西林的联合应用已在体外显示对结核分枝杆菌具有杀菌作用。这些数据表明，耐药结核病可能值得尝试采用包括阿莫西林-克拉维酸在内的治疗方案。
